AbbVie Reports Late-Breaking Results from Phase 3 Trial of HUMIRA, Has Met Primary Endpoint in PIONEER II
October 13, 2014 at 09:21 AM EDT
AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in ...